MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$21,231,140
(-94.49%↓ Y/Y)
Net loss
attributable to...
-$6,878,606
(-1056.07%↓ Y/Y)
Net loss
-$28,109,746
(-144.19%↓ Y/Y)
Income tax expense
(benefit)
-$231,210
(-187.50%↓ Y/Y)
Gain on sale of new
jersey net operating...
$3,833,277
Interest income
$53,584
(299.49%↑ Y/Y)
Gross Product Revenue
$2,003,760
Loss before income
taxes
-$28,340,956
(-151.98%↓ Y/Y)
Total other income,
net
$3,853,830
(28632.05%↑ Y/Y)
Revenues
$1,667,298
Interest expense
$33,031
Grosstonet Adjustments
$336,462
Operating loss
-$32,194,786
(-185.90%↓ Y/Y)
Gross profit
$1,338,420
Cost of revenues
$328,878
Total operating
expenses
$33,533,206
(197.79%↑ Y/Y)
General and
administrative
$26,391,101
(450.72%↑ Y/Y)
Stock-based compensation
general and...
$3,788,275
(40.20%↑ Y/Y)
Amortization of in-process
research and development
$1,720,312
Research and development
$1,633,518
(-56.63%↓ Y/Y)
Back
Back
Income Statement
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
source: myfinsight.com